Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Expansive Portfolio of Hematology/Oncology Data at the 65th American Society of Hematology Annual Meeting and Exposition
[ad_1]
Oral Presentations
Abstract and
Session No.
Title
Presentation Date/Time
Abstract 181
(Session 624)
Nivolumab-AVD Is Better Tolerated and
Improves Progression-Free Survival
Compared to Bv-AVD in Older Patients
(Aged ≥60 Years) with Advanced Stage
Hodgkin Lymphoma Enrolled on SWOG
S1826 Clinically Relevant Abstract
Saturday, December 9, 2023:
2:00 PM PT
Abstract 308
(Session 627)
Improved Survival of R/R Double Hit/Triple
Hit Lymphoma in the Era of CD19 Chimeric
Antigen T Cell (CART) Therapy
Saturday, December 9, 2023:
4:15 PM PT
Abstract 382
(Session 905)
Treatment Patterns and Outcomes for Patients
with Classic Hodgkin Lymphoma (cHL) and
Cardiomyopathy with Low Ejection Fraction
(EF): Real-World Evidence (RWE) from 16
US Academic Centers
Saturday, December 9, 2023:
4:45 PM PT
Abstract 497
(Session 905)
Outcomes of Patients with Richter
Transformation without Prior
Chemoimmunotherapy for CLL/SLL: An
International Multicenter Retrospective Study
Sunday, December 10, 2023:
10:30 AM PT
Abstract 603
(Session 623)
Mosunetuzumab Monotherapy Continues to
Demonstrate Durable Responses in Patients
with Relapsed and/or Refractory Follicular
Lymphoma after ≥2 Prior Therapies: 3-Year
Follow-up from a Pivotal Phase II Study
Sunday, December 10, 2023:
5:00 PM PT
Abstract 607
(Session 624)
Results from an Intergroup Randomized
Phase II Study of the Combinations of
Ipilimumab, Nivolumab and Brentuximab
Vedotin in Patients with Relapsed/Refractory
Classic Hodgkin Lymphoma: A Trial of the
ECOG-ACRIN Research Group (E4412)
Sunday, December 10, 2023:
4:30 PM PT
Abstract 610
(Session 624)
Progression-Free Survival (PFS) and Toxicity
with Nivolumab-AVD Compared to
Brentuximab Vedotin-AVD in Pediatric
Advanced Stage (AS) Classic Hodgkin
Lymphoma (cHL), Results of SWOG S1826
Sunday, December 10, 2023:
5:15 PM PT
Abstract 614
(Session 627)
Mosunetuzumab Monotherapy Demonstrates
Activity and a Manageable Safety Profile in
Patients with Relapsed or Refractory
Richter’s Transformation
Sunday, December 10, 2023:
4:45 PM PT
Abstract 981
(Session 623)
Pirtobrutinib in Relapsed/Refractory (R/R)
Mantle Cell Lymphoma (MCL) Patients with
Prior cBTKi: Safety and Efficacy Including
High-Risk Subgroup Analyses from the Phase
1/2 BRUIN Study
Monday, December 11, 2023:
5:00 PM PT
Poster Presentations
Abstract and
Session No.
Title
Presentation Date/Time
(Session 101)
Congenital Dyserythropoietic Anemia Type
II: An Update from the Congenital
Dyseryhtropoietic Anemia Registry of North
America (CDAR)
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 603)
Acetyl Transferase EP300 Deficiency Leads
to Chronic Replication Stress in Adult T-Cell
Leukemia/Lymphoma
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 616)
A Phase Ib/II Study Evaluating Navitoclax
after Failure of Hypomethylating Agent and
Venetoclax for Treatment of Relapsed or
Refractory High-Risk Myelodysplastic
Syndrome
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 622)
Alterations in Immune Cell Composition
during First-Line Therapy with
Mosunetuzumab for Follicular or Marginal
Zone Lymphoma
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 623)
Pirtobrutinib, a Highly Selective, Non-
Covalent (Reversible) BTK Inhibitor in
Relapsed / Refractory Marginal Zone
Lymphoma: Results from Phase 1/2 BRUIN
Study
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 626)
Multicenter Pilot Trial of Intrathecal
Liposomal Cytarabine Combined with FAB
Chemoimmunotherapy with Reduced
Doxorubicin in CAYA with Mature De-Novo
B-NHL
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 626)
Pirtobrutinib in Richter Transformation:
Updated Efficacy and Safety Results with 18-
Month Median Survival Follow-up from the
Phase 1/2 BRUIN StudyClinically Relevant
Abstract
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 627)
Immune Reconstitution and Infection Patterns
Following CAR T-Cell Therapy in Patients
with Aggressive LymphomaClinically
Relevant Abstract
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 642)
Treatment Effectiveness with Venetoclax-
Based Therapy after Bruton Tyrosine Kinase
Inhibitors in Chronic Lymphocytic Leukemia:
An International Real-World Study
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 703)
CD22 TCR-Engineered T Cells Exert Anti-
Leukemia Cytotoxicity without Causing
Inflammatory Responses
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 704)
Preliminary Results of Nathali-01: A First-in-
Human Phase I/IIa Study of UCART20x22, a
Dual Allogeneic CAR-T Cell Product
Targeting CD20 and CD22, in Relapsed or
Refractory (R/R) Non-Hodgkin Lymphoma
(NHL)
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 722)
Outcomes after RIC and Abatacept-Based
Acute and Chronic Gvhd Prophylaxis in
Allogeneic Transplantation for Sickle Cell
Disease – Can Calcineurin Inhibitor Use be
Curtailed?
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 903)
No Place like Home: Home-Based
Intravenous Arsenic Trioxide for the
Treatment of Acute Promyelocytic Leukemia
(APL)
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 905)
Exploration of Language As a Barrier to the
Assessment and Management of CAR T-Cell
Therapy Associated Toxicities
Saturday, December 9, 2023,
5:30 PM-7:30 PM PT
(Session 623)
GLOBRYTE: A Phase III, Open-Label,
Multicenter, Randomized Trial Evaluating
Glofitamab Monotherapy in Patients with
Relapsed or Refractory Mantle Cell
Lymphoma
Sunday, December 10, 2023,
6:00 PM-8:00 PM PT
(Session 624)
Development and Validation of the Early-
Stage Hodgkin Lymphoma (HL) International
Prognostication Index (E-HIPI): A Report
from the Hodgkin Lymphoma International
Study for Individual Care (HoLISTIC)
Consortium
Sunday, December 10, 2023,
6:00 PM-8:00 PM PT
(Session 624)
Identification of Risk Categories from the
Advanced-Stage Hodgkin International
Prognostic Index (A-HIPI) Model: A Detailed
Analysis from the Hodgkin Lymphoma
International Study for Individual Care
(HoLISTIC) Consortium
Sunday, December 10, 2023,
6:00 PM-8:00 PM PT
(Session 624)
AHOD2131: A Randomized Phase 3
Response-Adapted Trial Comparing Standard
Therapy with Immuno-Oncology Therapy for
Children and Adults with Newly Diagnosed
Stage I and II Classic Hodgkin Lymphoma
Sunday, December 10, 2023,
6:00 PM-8:00 PM PT
(Session 652)
Health-Related Quality of Life (HRQoL)
Among Patients with Triple-Class Exposed
Relapsed/Refractory Multiple Myeloma
(RRMM) Treated with Linvoseltamab in
Linker-MM1: Interim Assessment up to 36
Weeks of TreatmentClinically Relevant
Abstract
Sunday, December 10, 2023,
6:00 PM-8:00 PM PT
(Session 624)
Age-Based Validation of the Advanced-Stage
Hodgkin Lymphoma International Prognostic
Index (A-HIPI) in a Real-World Danish
Study: Suboptimal Performance in Older
Patients
Monday, December 11, 2023,
6:00 PM-8:00 PM PT
(Session 626)
Odronextamab Demonstrates Durable
Complete Responses in Patients with Diffuse
Large B-Cell Lymphoma (DLBCL)
Progressing after CAR-T Therapy: Outcomes
from the ELM-1 Study
Monday, December 11, 2023,
6:00 PM-8:00 PM PT
(Session 653)
Patterns of Response to 200 Mg
Linvoseltamab in Patients with
Relapsed/Refractory Multiple Myeloma:
Longer Follow-Up of the Linker-MM1 Study
Monday, December 11, 2023,
6:00 PM-8:00 PM PT
(Session 721)
Abatacept-Prophylaxis Based Haploidentical
Transplantation May Allow Sustained
Engraftment and Offset Gvhd in Non-
Malignant Disorders
Monday, December 11, 2023,
6:00 PM-8:00 PM PT
Education Program
N/A
Saturday, December 9, 2023,
2:00 PM-3:15 PM PT
N/A
Hodgkin Lymphoma Treatment for Older Persons in the Modern Era
Saturday, December 9, 2023,
4:00 PM-5:15 PM PT
N/A
How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?
Saturday, December 9, 2023:
4:00 PM-5:15 PM PT
Program: Special-Interest Sessions
Session 2
Sunday, December 10, 2023,
7:30 AM-9:30 AM PT
[ad_2]
